Glenmark launches Tavulus for COPD treatment in Spain

COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissues and narrow airways all of which makes breathing difficult. Studies show that close to 2.5 million people suffer from COPD in Spain, the pharma company release said.

Tavulus is expected to provide relief to a large lung patient population in the country.

It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs and also works to prevent sudden, short-term worsening of COPD symptoms.

Commenting on the launch, Vice President - Business Development of Glenmark Pharmaceuticals Limited, Dr Jiri Havranek, said, “The goal of COPD treatment has always been to provide quick symptomatic relief to patients and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets, and we are pleased to extend these benefits to patients in Spain."

"This inhalation therapy has been shown to significantly aid in the daily management of COPD. We hope that it improves both COPD symptoms and quality of life in those who are most affected,'' he said.